Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Otsuka Holdings Co Ltd Announces Approval for Abilify Maintena of Subsidiary and H Lundbeck A/S in Europe


Thursday, 21 Nov 2013 02:00am EST 

Otsuka Holdings Co Ltd announced that its subsidiary Otsuka Pharmaceutical Co., Ltd. and H Lundbeck A/S announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole. Abilify Maintena reduces the risk of relapse relative to placebo over the long-term and provides treatment of schizophrenia. 

Company Quote

132.5
7.5 +6.00%
7:36am EDT